sever
fever
thrombocytopenia
syndrom
viru
sftsv
newli
discov
member
bunyavirida
famili
caus
agent
emerg
hemorrhag
fever
sft
china
current
vaccin
effect
therapi
sft
studi
combinatori
human
antibodi
librari
construct
peripher
lymphocyt
patient
recov
sft
librari
screen
purifi
virion
product
singlechain
variableregion
fragment
scfv
posit
clone
one
clone
monoclon
antibodi
mab
show
neutral
activ
sftsv
infect
vero
cell
mab
found
effect
neutral
clinic
isol
sftsv
test
isol
patient
china
mab
found
bind
linear
epitop
ectodomain
glycoprotein
gn
neutral
activ
attribut
blockag
interact
gn
protein
cellular
receptor
indic
inhibit
viruscel
attach
main
mechan
data
suggest
mab
use
promis
candid
molecul
immunotherapi
sftsv
infect
mab
recombin
gnha
fusion
protein
unabl
bind
vero
cell
incub
mab
scfv
nonneutr
antibodi
use
neg
control
ever
fever
thrombocytopenia
syndrom
sft
emerg
fatal
hemorrhag
fever
fatal
case
diseas
caus
newli
identifi
bunyaviru
sft
viru
sftsv
character
sudden
onset
fever
respiratori
gastrointestin
symptom
decreas
whole
white
blood
cell
platelet
count
gradual
progress
hemorrhag
multiorgan
failur
end
stage
diseas
report
across
broad
geograph
area
eastern
central
china
includ
jiangsu
anhui
shandong
henan
hubei
liaon
provinc
heighten
surveil
acut
febril
ill
led
research
add
zhejiang
southeastern
provinc
list
region
sftsv
endem
indic
diseas
continu
spread
china
recent
bunyaviru
name
heartland
viru
hlv
isol
patient
missouri
unit
state
hlv
homolog
chines
viru
base
amino
acid
sequenc
clinic
symptom
hlv
infect
similar
caus
sftsv
one
case
human
sft
outsid
china
report
demonstr
sftsv
viru
similar
sftsv
probabl
worldwid
distribut
although
human
sft
case
china
sporad
patient
tend
histori
arthropod
bite
persontoperson
transmiss
blood
contact
report
despit
medic
import
diseas
clinic
treatment
sftsv
infect
support
care
develop
prophylact
therapeut
measur
includ
therapeut
antibodi
vaccin
would
protect
suscept
individu
high
risk
complic
infect
urgent
need
sftsv
member
phleboviru
genu
bunyavirida
famili
like
bunyavirus
sftsv
triseg
singlestrand
rna
genom
neg
l
segment
ambisens
segment
polar
encod
seven
protein
two
glycoprotein
gn
gc
produc
cleavag
precursor
encod
segment
highli
antigen
envelop
protein
respons
receptor
bind
membran
fusion
reason
viral
surfac
glycoprotein
may
target
neutral
antibodi
respons
antibodi
play
critic
role
treatment
wide
varieti
viral
diseas
caus
hantaan
viru
cytomegaloviru
rabi
viru
respiratori
syncyti
viru
infect
mechan
antibodi
protect
includ
neutral
complement
activ
antibodydepend
cellular
cytotox
opson
patient
infect
sftsv
like
infect
system
arbovirus
remain
virem
day
unpublish
data
administr
neutral
antibodi
conceiv
reduc
viral
load
prevent
viral
dissemin
system
like
reduc
risk
sever
outcom
diseas
could
also
use
prophylact
highrisk
person
hospit
personnel
famili
member
patient
risk
persontoperson
transmiss
immunocompromis
patient
might
respond
well
vaccin
studi
develop
human
monoclon
antibodi
mab
call
mab
isol
phage
antibodi
librari
use
whole
sftsv
virion
bind
neutral
properti
investig
mab
found
bind
linear
epitop
ectodomain
gn
unidentifi
epitop
found
conserv
among
dispar
geograph
viru
isol
within
china
sinc
mab
show
crossneutr
activ
mode
inhibit
also
character
indic
mab
mediat
neutral
block
bind
gn
cellular
receptor
data
suggest
mab
could
develop
therapeut
agent
passiv
immunotherapi
sftsv
use
studi
list
tabl
propag
vero
cell
multipl
infect
moi
cultiv
day
supernat
contain
viral
particl
harvest
aliquot
store
use
fiftyperc
tissu
cultur
infect
dose
tcid
work
stock
strain
titrat
vero
cell
virion
purif
cultur
supernat
viru
success
treat
inactiv
remov
cell
debri
ultracentrifug
gel
filtrat
chromatographi
describ
previous
purifi
virion
analyz
sdspage
confirm
puriti
oper
involv
sftsv
perform
biosafeti
level
contain
condit
construct
pan
screen
human
singlechain
variableregion
fragment
scfv
antibodi
librari
human
lymphocyt
collect
convalesc
sft
patient
jiangsu
provinc
research
protocol
approv
human
bioethic
committe
jiangsu
center
diseas
prevent
control
jiangsu
cdc
particip
provid
written
inform
consent
total
rna
extract
lymphocyt
use
rna
purif
kit
qiagen
valencia
ca
firststrand
cdna
synthes
total
rna
use
firststrand
cdna
synthesi
kit
invitrogen
carlsbad
ca
oligo
dt
variableregion
gene
heavi
vh
light
vl
chain
amplifi
cdna
use
pcr
sequenti
clone
phagemid
vector
describ
elsewher
human
antibodi
librari
construct
electrotransform
scfv
gene
reservoir
escherichia
coli
stratagen
la
jolla
ca
costar
eiaria
stripwel
immunopl
corn
ny
coat
sftsv
virion
dilut
concentr
gml
carbonatebicarbon
buffer
ph
lwell
incub
overnight
phage
incub
sftsv
h
bound
phage
elut
use
reinfect
e
coli
reamplifi
describ
previous
round
pan
phage
individu
coloni
test
bind
sftsv
enzymelink
immunosorb
assay
elisa
posit
clone
gene
vh
vl
chain
sequenc
correspond
amino
acid
sequenc
align
express
solubl
scfv
mab
solubl
scfv
express
e
coli
invitrogen
la
jolla
ca
purifi
periplasm
fraction
scfv
contain
tag
carboxi
terminu
facilit
purif
immobil
metal
affin
chromatographi
engin
product
human
immunoglobulin
mab
perform
larg
describ
previous
briefli
vh
vl
region
scfvposit
clone
pcr
amplifi
use
specif
primer
clone
baculoviru
vector
via
xhoinhei
sacihindiii
site
mab
express
cotransfect
recombin
plasmid
linear
acnpv
baculoviru
dna
bd
san
jose
ca
insect
cell
accord
manufactur
instruct
supernat
contain
recombin
human
purifi
protein
g
column
ge
healthcar
uppsala
sweden
kept
use
neutral
assay
first
l
sftsvspecif
scfv
g
ml
mix
equal
volum
suspens
tcid
sftsv
strain
incub
h
virusantibodi
mixtur
transfer
onto
monolay
vero
cell
plate
incub
h
wash
minim
essenti
medium
mem
mainten
medium
sampl
incub
co
incub
cytopath
effect
cpe
observ
everi
h
day
antibodi
consid
neutral
capac
could
inhibit
viral
cpe
posit
clone
design
mab
scfv
reformat
fulllength
molecul
use
character
neutral
potenc
crossbind
activ
describ
individu
measur
perform
triplic
rel
neutral
calcul
presenc
patient
convalescentphas
sera
irrelev
human
scfv
format
enteroviru
specif
posit
neg
control
respect
western
blot
analysi
determin
bind
target
select
mab
purifi
sftsv
strain
virion
lyse
sampl
buffer
protein
fraction
sdspage
separ
protein
electrotransf
nitrocellulos
nc
membran
incub
consequ
mab
horseradish
peroxidas
hrp
conjug
goat
antihuman
immunoglobulin
zhgbbio
beij
china
blot
visual
dab
boster
bio
wuhan
china
accord
manufactur
instruct
immunofluoresc
assay
reactiv
human
mab
sftsvinfect
cell
assess
use
indirect
immunofluoresc
assay
ifa
infect
noninfect
sftsv
vero
cell
grown
millicel
ez
slide
millipor
billerica
h
cell
fix
treatment
aceton
min
human
mab
irrelev
human
describ
incub
fix
cell
min
bound
antibodi
detect
use
fluorescein
isothiocyan
fitc
conjug
antihuman
antibodi
kpl
gaithersburg
md
dilut
phosphatebuff
salin
pb
contain
wtvol
even
blue
observ
immunofluoresc
microscop
electron
microscopi
immunoelectron
microscopi
immuneem
sftsv
virion
perform
essenti
describ
previous
sftsv
supernat
infect
vero
cell
adsorb
copper
grid
coat
carbon
pioloform
incub
mab
float
droplet
min
room
temperatur
irrelev
human
describ
use
neg
control
bound
monoclon
antibodi
detect
incub
droplet
antihuman
igg
gold
conjug
jieyi
biotech
shanghai
china
grid
neg
contrast
correspond
gene
gener
pcr
clone
express
vector
sequenc
confirm
dna
sequenc
function
domain
express
cell
transient
transfect
recombin
proteincontain
supernat
analyz
western
blot
describ
mechan
mab
neutral
activ
recombin
gn
ectodomaincontain
cultur
supernat
l
mix
excess
mab
scfv
g
anoth
select
clone
librari
call
use
neg
control
incub
overnight
proteinantibodi
mixtur
ad
vero
cell
suspens
mix
incub
room
temperatur
h
cell
wash
lyse
sampl
buffer
protein
analyz
western
blot
antihahrp
conjug
human
scfv
librari
pan
purifi
inactiv
sftsv
virion
coat
plastic
plate
round
pan
randomli
pick
clone
screen
clone
found
recogn
sftsv
elisa
data
shown
sequenc
analysi
posit
scfv
clone
reveal
presenc
uniqu
clone
fig
select
scfv
encod
differ
vh
vl
sequenc
gene
famili
vh
vl
clone
express
e
coli
purifi
immobil
metal
affin
chromatographi
vitro
neutral
activ
antibodi
sftsv
neutral
activ
purifi
solubl
scfv
sftsv
test
use
vero
cell
scfv
clone
test
clone
show
neutral
activ
fig
clone
convert
intact
express
baculovirusinsect
cell
system
determin
neutral
potenc
mab
subject
serial
dilut
increment
titrat
strain
shown
fig
mab
exhibit
far
potent
neutral
activ
sftsv
scfv
format
consist
superior
avid
concentr
requir
obtain
neutral
tcid
sftsv
gml
activ
achiev
mab
scfv
concentr
gml
control
antibodi
exhibit
neutral
activ
sftsv
neutral
breadth
mab
investig
use
panel
differ
sftsv
isol
obtain
region
sftsv
endem
includ
jiangsu
anhui
shandong
henan
zhejiang
tabl
mab
separ
incub
presenc
tcid
sftsv
isol
h
incub
vero
cell
complet
protect
sftsv
strain
achiev
dose
gml
mab
two
except
jiangsu
isol
mab
neutral
rate
respect
fig
indic
mab
recogn
conserv
epitop
within
sftsv
structur
protein
share
dispar
geograph
viru
isol
china
character
mab
bind
specif
western
blot
show
mab
immunoreact
two
band
molecular
mass
kda
kda
respect
reduc
condit
fig
probabl
repres
gn
glycoprotein
homoor
heterooligom
gn
gngc
observ
molecular
mass
compar
purifi
virion
sdspage
profil
fig
indic
recogn
continu
linear
epitop
within
gn
confirm
specif
mab
viru
immunofluoresc
perform
sftsvinfect
uninfect
vero
cell
sftsvinfect
cell
fix
slide
aceton
moder
stain
fig
wherea
fluoresc
could
detect
uninfect
cell
treat
mab
fig
control
human
nt
stain
either
infect
fig
uninfect
fig
cell
immuneem
use
investig
bind
mab
glycoprotein
whole
virion
incub
mab
caus
local
gold
label
outer
peplom
region
sftsv
strain
control
human
induc
label
fig
b
map
mab
bind
sftsv
glycoprotein
domain
protein
transmembran
helic
predict
use
tmhmm
server
version
one
ectodomain
identifi
gn
aa
gc
aa
map
region
bound
mab
gn
gc
ectodomain
express
separ
cell
western
blot
analysi
show
react
gn
gc
ectodomain
fig
b
suggest
mab
recogn
expos
loop
aa
n
terminu
gn
protein
fig
vero
cell
incub
recombin
gn
ectodomain
presenc
mab
scfv
analyz
western
blot
mab
scfv
complet
inhibit
bind
gn
vero
cell
nonneutr
antibodi
inhibit
bind
condit
demonstr
mechan
neutral
activ
mab
involv
block
bind
gn
cellular
receptor
china
sft
sever
emerg
hemorrhag
fever
caus
thousand
peopl
hospit
year
averag
case
fatal
vaccin
fig
probabl
repres
gn
glycoprotein
homoor
heterooligom
gn
gngc
compar
purifi
virion
sdspage
profil
fig
effect
countermeasur
viral
diseas
howev
low
incid
sporad
natur
sftsv
infect
make
difficult
target
human
popul
need
vaccin
access
vaccin
econom
feasibl
sever
influenc
vaccin
develop
antibodymedi
therapeut
may
use
contributor
treat
prevent
sft
use
suscept
individu
high
risk
complic
infect
studi
human
antibodi
sftsv
describ
actual
breadth
neutral
spectrum
function
activ
bind
target
also
investig
viral
envelop
glycoprotein
sftsv
gn
gc
mediat
receptor
attach
fusion
viral
cellular
membran
give
viral
genom
access
host
cell
cytoplasm
antibodi
inhibit
viral
infect
two
distinct
mechan
occur
parallel
stage
viral
entri
cell
directli
block
viral
attach
target
cell
interf
virusreceptor
interact
includ
antibodi
protein
sever
acut
respiratori
syndrom
coronaviru
sarscov
antibodi
envelop
protein
west
nile
viru
antibodi
also
target
viral
receptor
exemplifi
treatment
arenaviru
infect
antihuman
transfer
receptor
antibodi
viral
entri
via
endocytosi
antibodi
may
block
conform
chang
envelop
protein
requir
fusion
viral
endosom
membran
exampl
antihemagglutinin
mab
neutral
infect
influenza
viru
interf
low
phinduc
structur
rearrang
domain
inhibit
fusion
viral
replic
studi
consist
first
mechan
describ
mab
gener
memori
b
cell
repertoir
sft
convalesc
patient
found
neutral
sftsv
infect
interf
interact
viru
receptor
recombin
gn
ectodomain
bind
suscept
vero
cell
incub
mab
scfv
format
fig
structur
gn
gc
virus
bunyavirida
famili
typic
class
transmembran
protein
amino
termini
expos
surfac
virion
carboxi
terminu
anchor
membran
function
domain
predict
gn
sftsv
result
domain
map
mab
show
gn
domain
aa
locat
amino
terminu
bound
antibodi
demonstr
ectodomain
primari
domain
cellular
membran
attach
correspond
put
expos
loop
receptor
bind
bunyaviru
report
member
bunyavirida
viral
neutral
site
locat
gn
gc
present
studi
due
limit
number
clone
select
antibodi
describ
gn
identif
potenti
neutral
antibodi
gc
merit
explor
import
find
studi
may
one
antibodi
neutral
sftsv
strain
found
area
sftsv
endem
jiangsu
anhui
shandong
henan
zhejiang
potent
indic
epitop
mab
conserv
among
divers
sftsv
strain
singlestrand
rna
genom
genet
evolut
sftsv
may
accru
term
mutat
reassort
howev
littl
known
detail
process
uncharacter
epitop
resist
host
immun
pressur
play
critic
role
receptor
bind
take
place
viral
transmiss
mab
may
toler
antigen
variabl
circul
sftsv
variant
maintain
abil
neutral
virus
anoth
uniqu
featur
mab
react
linear
epitop
rather
conform
one
fig
may
facilit
ration
vaccin
design
data
underscor
import
broadli
crossreact
surfaceexpos
epitop
ntermin
domain
gn
design
protect
sftsv
vaccin
human
mab
gener
phageyeast
display
immort
human
b
cell
convalesc
patient
immun
transgen
mice
combin
antibodi
varieti
structur
epitop
glycoprotein
may
expand
breadth
protect
offer
limit
number
potenti
immun
escap
variant
howev
screen
neutral
antibodi
isol
one
clone
per
studi
sever
reason
may
account
although
phage
displaybas
select
current
commonli
use
method
develop
human
mab
inher
select
bias
difficult
control
pan
antibodi
fold
effici
posttransl
modif
epitop
access
differ
display
host
influenc
outcom
select
second
method
antigen
present
pan
may
affect
number
distribut
avail
neutral
epitop
studi
postul
expos
epitop
within
receptor
bind
domain
gn
protein
surfac
virion
easili
recogn
antibodi
mab
epitop
expos
viral
fusion
access
antibodi
select
condit
third
still
possibl
antibodi
clone
abund
viral
antigen
eg
nucleocapsid
protein
may
overshadow
glycoprotein
pan
might
otherwis
screen
new
strategi
may
requir
deplet
librari
phage
bind
irrelev
target
enhanc
specif
clone
enrich
ratio
summari
mab
newli
discov
human
neutral
antibodi
capabl
recogn
broadli
crossreact
surfaceexpos
epitop
ntermin
domain
sftsv
gn
glycoprotein
work
requir
delin
precis
structur
epitop
may
import
implic
design
vaccin
capabl
elicit
protect
mab
antibodi
respons
sinc
result
report
gener
vitro
antivir
activ
mab
vivo
way
laboratori
overal
mab
may
use
promis
candid
molecul
emerg
prophylaxi
treatment
sftsv
infect
